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ABSTRACT   
Through further development, integration and validation of micro-nano-bio and biophotonics systems FP7 CanDo is 
developing an instrument that will permit highly reproducible and reliable identification and concentration determination 
of rare cells in peripheral blood for two key societal challenges, early and low cost anti-cancer drug efficacy 
determination and cancer diagnosis/monitoring.  
 
A cellular link between the primary malignant tumour and the peripheral metastases, responsible for 90% of cancer-
related deaths, has been established in the form of circulating tumour cells (CTCs) in peripheral blood. Furthermore, the 
relatively short survival time of CTCs in peripheral blood means that their detection is indicative of tumour progression 
thereby providing in addition to a prognostic value an evaluation of therapeutic efficacy and early recognition of tumour 
progression in theranostics. In cancer patients however blood concentrations are very low (=1 CTC/1E9 cells) and 
current detection strategies are too insensitive, limiting use to prognosis of only those with advanced metastatic cancer. 
Similarly, problems occur in therapeutics with anti-cancer drug development leading to lengthy and costly trials often 
preventing access to market.  
 
The novel cell separation/Raman analysis technologies plus nucleic acid based molecular characterization of the CanDo 
platform will provide an accurate CTC count with high throughput and high yield meeting both key societal challenges. 
Being beyond the state of art it will lead to substantial share gains not just in the high end markets of drug discovery and 
cancer diagnostics but due to modular technologies also in others. Here we present preliminary DNA hybridization 
sensing results. 
 
Keywords: Circulating Tumour Cells, silicon nitride waveguides, Mach Zhender Interferometry, Multimode 
Interference, Arrayed Waveguide gratings, AlOx sacrificial layer, azide organosilanes, DNA hybridization, 
 
1. CTC DETECTION TECHNOLOGIES 
1.1. A Point of Care Diagnostic Challenge 
Some diagnostic applications are extremely demanding, such as those requiring both the identification and concentration 
determination of extremely low levels of cells in peripheral blood, that to date no such point of care (PoC) diagnostic 
technology generic or otherwise exists for these. One such application is for the recognition and the concentration 
measurement of rare circulating tumour cells (CTCs) for early diagnosis staging and monitoring of cancer. Pancreatic 
cancer is one such target, and is of strong socio-economic interest as currently it is usually diagnosed at an advanced 
stage when rapid progression has occurred for widespread disease dissemination and so a 96% chance of death for some 
68000 Europeans diagnosed every year. A powerful tool for correct diagnosis and staging of pancreatic cancer would 
permit not just advances in cancer management, where clinicians could prescribe a suitable early treatment and monitor 
its progress within theranostics, but also in drug discovery for quick and accurate determination of the effectiveness of 
new anti-cancer drugs in development tests. 
1.2. State of art 
The detection and molecular characterization of CTCs are one of the most active areas of translational cancer research, 
with > 400 clinical studies having included CTCs as a biomarker [1]. There is a battery of analytical tools available for 
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the analysis and characterization of cells once isolated, including immunochemistry and nucleic acid analysis. However, 
CTCs are rare even in patients with advanced cancer, as low as 1 CTC in 1 billion blood cells. Furthermore, the 
techniques currently used to isolate these CTCs require laborious manual sample preparation steps that result in highly 
variable results and low sensitivity. A reliable rare cell sorter technology for CTCs is therefore exceedingly challenging. 
Some of the current commercially available CTC isolation methods are described in Table 1.  
Table 1: CTC detection technologies 
Technology Name Company Name Isolation Method/ Assay  Detection Method 
CTC 
Count 
Molecular 
Analysis 
AdnaTest AdnaGen,  Immuno/Enrichment + Characterization No Yes 
ApoStreamTM ApoCell, Inc Electrical + Immuno/Enrichment Yes No 
IsoFlux Fluxion Bioscience, 
Inc  
Electrical + Immuno/Enrichment + 
Characterization 
Yes No 
CellSearchTM Veridex Immuno/ Enrichment + Enumeration Yes No 
CaptorTM Abnova, Taipei,  Size/Enrichment + Enumeration + 
Characterization 
Yes No 
DEPArray Silicon Biosystems,  Electrical/ Enumeration Yes No 
Epic HD-CTC Assay Epic Science, Inc Immuno/Enumeration + Characterization Yes No 
CellCollector GILUPI  Invivo (immuno)/Enrichment + enumeration 
Enumeration + Characterization 
Yes No 
OncoCEE-BR TM Biocept, Inc  Immuno/Enumeration + characterization  Yes No 
Cytotrack CT4 CytoTrack ApS Immuno/Characterization Yes No 
ScreenCell Screen Cell,  Size/Enrichment + characterization Yes No 
CanDo platform CanDo Consortium size + Immuno/Enrichment + enumeration + 
characterization 
Yes Yes 
 
The current “gold standard” for CTC isolation and CTC enumeration is the Cellsearch® System by Veridex, an affiliate 
of Johnson & Johnson. The CellSearch® System is the first and only 510(k) diagnostic test used to automate the capture 
and detection of CTCs, tumour cells that have detached from solid tumours and entered the patient’s blood. The 
CellSearch System is focused on isolating CTCs from the peripheral blood using immunomagnetic beads conjugated 
with EpCAM [2]. This FDA approved technology sets the standard for patients with metastatic breast, prostate or 
colorectal cancer. Patients in the non-metastatic setting or with other tumour indications are not eligible to benefit from 
this technology. However, its success has been seriously hampered by very low yield and purity of isolated CTCs [3]. 
The low yield of immunomagnetic isolation of CTCs is likely to reflect the fact that these cells are very rare and do not 
readily survive the multi-step batch purification technique involved. A reliable clinical test that can confirm that a patient 
is free of circulating tumour cells is of great value for the patient in a staging situation or in a situation of follow up after 
successful treatment. 
 
All-in-all current commercial technologies are semi-automated at best with multiple “bulk” enrichment steps such as 
magnetic particle sorting. As a result, the sensitivity and specificity of CTC detection and analysis is very low, highly 
variable, and not very useful for a clinical test.  
 
1.3. Moving beyond state of art  
In CanDo, through the integration of various components and sub-systems recently developed in other projects a 
diagnostic platform is targeted that will enable accurate and reliable early pancreatic cancer diagnosis, monitoring and 
prognosis determination based on efficient capture and recognition of CTCs in peripheral blood at unprecedented limits 
of detection.  
The targeted approach (Figure 1) is based on a disposable cartridge system that combines a powerful cell separation 
technology; principally through a combination of the GILUPI system [4] or inertial microfluidics [5] and high yield 
sensitive immuno-capture, with Raman spectroscopy to identify/quantify the CTC and sensitive nanophotonic sensors for 
nucleic acid analysis from the lysed CTCs for molecular characterization. Not only should the sensors be sensitive but 
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they and their instrumentation should also be capable of multiplexing of up to 20 times and be of a suitably low cost to 
make the overall platform competitive. In this paper we present some preliminary results of some novel sensors that 
would meet such criteria. 
 
Figure 1. A schematic of the principally targeted CanDo platform with indicated components and sub-systems. The platform achieves 
cancer diagnosis through CTC capture and enumeration (cellular characterization) followed by nucleic acid analysis (molecular 
characterization). It takes whole blood from cancer patient and isolates the CTCs using a novel in-vivo isolation technology (whilst 
another in-vitro technology is considered as a backup) to deliver cell enumeration. The enumerated cells are then further processed for 
nucleic acid characterization using a label-free photonic sensor array.  
 
2. NANOPHOTONIC BIOSENSORS 
2.1. State of art 
Biosensors are by definition a combination of a biological receptor molecule and a physical or physicochemical 
transducer [6]. The main challenge for biosensor technologies in diagnostics and other biosensing applications is the 
rapid detection of low concentration of a specific analyte in small sample volumes typically in a complex mixture with 
large background signals (a problem known as non-specificity).  
 
Optical methods of transduction offer important advantages such as non-invasive/safe, label free and multi-dimensional 
(intensity, wavelength, phase, polarization) high sensitivity detection across optical frequencies that coincide with a wide 
range of physical properties of bio-related materials. Within the important category of label free biosensing, optical 
transducers have a significant presence: indeed, the dominant vendor of label free technology is Biacore, and their 
technology is a photonic one, based on surface plasmon resonance. However, the detection limit of this technology is 
inherently limited due to absorption effects in the metal. Nevertheless, with measurements of optical absorption and 
refractive index (RI) being well established analysis methods in chemistry and biology they have been incorporated in 
label-free biosensor based lab-on-chip solutions through technologies such as surface plasmon resonance (SPR) [7][8] as 
well as others based on thin-film interference spectroscopy [9], or optical waveguides [10].  
 
In the quest for label free lab-on-a-chip systems with lower limits of detection an alternative optical biosensing 
technology to SPR and its metallic structures has arisen based on dielectric structures [11]. Specifically, recent maturity 
in silicon photonics technology that operates in the near infra-red (NIR) has led to advances in the employment for 
sensing of the evanescent field of guided modes in high-index core dielectric waveguides such as interferometers [12], 
photonic crystals [13], microsphere resonators [14] and silicon ring resonators – the latter having achieved detection 
limits down to the femtomolar range for proteins [15]. Their compatibility with mature silicon microprocessing 
technologies and materials have permitted a high integration of complex structures, on-chip integration of electronics 
and, via the addition of polymers, microfluidic channels for high-throughput arrays on a single-chip for simultaneous 
detection of multiple analytes. These devices with optical transmission lengths in the order of millimetres achieve 
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surface concentration detection limit (SCDL) values in the order of 0.1 - 1pg/mm2 and so in recent years, the EU has 
funded relevant projects regarding optical biosensing systems based on these [16]. Table 2 summarises the results from 
two of these, SABIO [17] and InTopSens [18]. 
 
Table 2: A summary of main achievements and problems encountered in two recent EC projects. UPV corresponds to the group of A. 
Maquieira at the Technical University of Valencia and IMEC to that of T. Stakenborg at IMEC. 
Project Technology Main Achievements Problems encountered 
SABIO SiN slot ring 
resonators with 
UPV chemistry 
Methanol/Ethanol dilution series detection:  5x10-6 RIU. 
Glutaraldehyde-AntiBSA detection: successful detection of 
0.9 pg/mm2, a significant improvement on a previously 
published value of 28 pg/mm2. 
Poor resolution due to 
fabrication technology 
limitations (sidewall 
roughness).   
InTopSens Si slot ring 
resonators with 
UPV chemistry 
Aqueous salt solution detection: 4.2x10–5 RIU Biotin-avidin 
detection: 5pg/mm2 
Lower resolution than SABIO 
device principally due to 
bending and mismatch losses. 
InTopSens Si ring resonators 
with UPV chemistry 
Aqueous salt solution detection: 5x10–6 RIU Biotin-avidin 
detection: 2pg/mm2. High degree of multiplexing achieved. 
Instrumentation cost very 
expensive (tunable laser). 
InTopSens Vernier cascade Si 
ring resonators with 
UPV chemistry 
Aqueous salt solution detection: 8.3x10–6 RIU.  DNA 
detection: Cheaper readout but poorer LoD than regular ring 
resonators. Inherently temperature stable. 
Surface chemistry issues 
prevented successful detection 
of on-chip hybridisation. 
Post 
InTopSens 
Regular Si ring 
resonators with 
IMEC chemistry 
DNA detection: 100 nM 25 bp, to be compared to the best 
published result of 10pM of 58mers for a biomodal 
interferometer [19]. 
Limitation to multiplexing 
capability. 
 
However, none of these have been commercialized and it is debatable whether, the Maverick Technology, based on 
(non-slot waveguide) ring resonators fabricated by IMEC, of Genalyte will be a commercial success for the same reason 
– they require a high performance and therefore costly tuneable laser. In the case of the Genalyte system, its sale cost is 
anywhere between 50 and 100k€ which automatically limits it to niche applications, almost all being non-point of care, 
across healthcare, food safety, environment, security markets. Low cost ring resonator technologies such as the 
‘Verniers’ [20] with their cheap broadband light sources have similar sensitivities but their on-chip spectrum analysers 
with resolutions of only 1nm are no match for the expensive external spectrum analysers, resulting overall in poorer 
limits of detection. Moreover, they are more limited for multiplexing. 
 
2.2. Moving beyond state of art 
2.2.1. Si3N4 integrated unbalanced Mach-Zehnder Interferometer  
Photonic biosensors (Figure 2) based on a silicon nitride (Si3N4) integrated unbalanced Mach-Zehnder Interferometer 
(MZI) have been developed in the FP7 POCKET project by two of us (Mertens and Bienstman). Such biosensors have 
been shown to have both sufficient multiplex capability and limit of detection for the CanDo application and cost up to 
15x less than the aforementioned technologies in section 2.1 that operate at wavelengths of 1300 or 1550nm. In order for 
their implementation to be low cost, an 850 nm free space SLED broadband source has been used as the incident light 
and, an on-chip arrayed waveguide grating (AWG) [21], filters the output MZI spectrum prior to the light exiting the 
chip. Specifically, the light is coupled into the on chip optical circuit through a 16º vertical grating coupler, before being 
guided along a monomode strip waveguide until its division between two arms using a MMI coupler. The whole circuit 
is covered with an oxide cladding layer except the sensing waveguide which is exposed to the analyte. The light from 
both arms are combined using a second MMI coupler, so there is an intensity modulation at its output depending on the 
phase shift introduced by the sample to be measured over the sensing branch. The MZI output is then filtered through the 
AWG into 30 channels with 1nm bandwidth each, and the light is coupled out of the circuit over 30 grating couplers. The 
output optical intensity from the couplers is measured by a CCD camera over a lens, and proprietary software fits peaks 
to the spectra and represents the MZI output modulation. The different designs of the MZI biosensors (MZI1, MZI2, 
MZI3 etc) on each chip in the reported experiments (Figure 3) permitted different sensitivities. Each chip contained 7 
Input grating couplers, 6 different sensors, 7 AWG filters, 210 output grating couplers (6 sensors by 30 output AWG 
channels and 30 more for the reference) with the input and output couplers orthogonal for reducing scattering. Although 
each chip of biosensors used was identical those functionalised in one batch were labelled as HULKx and those in 
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Figure 2. Schematic of the nanophotonic integrated biosensor circuit. 
 
 
 
Figure 3. Components distribution of the fabricated and analysed chip 
 
2.2.2. DNA sensor functionalisation 
Synthetic hexynyl-modified single strand DNA (ssDNA) probes were covalently bonded to the functionalised surface of 
the MZI sensing waveguides through the use of standard click chemistry. The surface was functionalised with azide 
organosilanes previously immobilized using a vapour phase deposition method (145°C, 25mbar). 
 
2.2.3. Experimental setup 
The setup (Figure 4) includes a syringe pump to flow a hybridization buffer (1M NaCl, 10 mM Tris.HCl, and 2mM 
EDTA; pH 7) at 10 µL/min towards the chip via a valve which is switched to allow the ssDNA analyte to flow through 
an inlet tube and into a PDMS (PolidimetilSiloxane) microfluidic channel on the surface of the chip that conducts the 
sample over the surface of the sensing arm waveguide. The output of the microfluidic channel thereafter passes into an 
outlet tube and onto the waste chamber. The chip is mounted on an aluminium plate with a Peltier element which is 
connected to a temperature controller to fix the chip temperature to 303.45K. The optical source with a collimator is 
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mounted on a three axis micro-positioner to align the light spot onto the input grating couplers of the chip. The intensity 
of the 30 output light spots is measured by a CCD camera and the control computer software detects the wavelength 
shifts. 
 
 
Figure 4. Schematic of the DNA detection setup 
 
2.2.4. Experimental measurements 
Before the start of DNA detection, the sensing surfaces within the microfluidic system were rinsed with injections of 
isopropanol and distilled water followed by HCl to regenerate the surface. Afterwards, the DNA hybridization buffer was 
injected at a rate of 10 µL/min to allow the surface of the waveguide to capture the complementary ssDNA analyte. Once 
the peak wavelength was stable, and with the buffer still flowing, injections of the analyte (a 25mers complementary 
ssDNA) at concentrations of 5pM, 50pM, 500pM, 5nM, 50nM, 400nM were introduced, each separated by HCl 
injections to regenerate the surfaces.  
 
Figure 5 shows sensorgrams for four different DNA concentrations on four different sensors within chips Spiderman1, 2 
and 3. Figure 5a shows the detection of just 5pM of ssDNA from a wavelength shift of 50pm although the noise level is 
around 18pm.  
 
Figure 6a shows the measured peak wavelength shift over different DNA concentrations, from 50pM upwards, on MZI4 
and MZI6 sensors (both on chip HULK4). From linear fits to this preliminary data a 23pm/pM sensitivity was derived 
for the sensor MZI4, and 37pm/pM for MZI6. Figure 6b shows measurements from an experiment with a sensor of the 
same design (MZI4) on a chip functionalised in a separate batch, Spiderman4. In this experiment HCl was not injected 
between samples, and so the DNA concentration range extends up to 455nM. From a linear fit over the first three data, 
the derived sensitivity is similar to that of that on Hulk4 at 17nm, with the difference possibly due to differences in 
surface activity being functionalised in two different batches. 
 
The wavelength dependency on temperature has also been studied. Figure 7 shows that MZI4 on the Spiderman4 chip 
has a temperature sensitivity of -54.9pm/K. 
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Figure 5. Measured sensorgrams at different concentrations of 25-mers DNA fragments on different sensors. 
 
 
Figure 6. Measured wavelength shifts for given ssDNA analyte concentrations for sensors MZI4 and MZI6 on chip Hulk4 with HCl 
injections between samples (a), and MZI4 on chip Spiderman4 without HCl injections between samples (b).  
 
 
Figure 7. Peak wavelength over temperature for MZI4 on chip Spiderman4. 
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3. CONCLUSIONS 
A low cost, potentially highly multipliexed biosensor design based on an integrated unbalanced silicon nitride 
nanophotonic Mach-Zehnder Interferometer integrated together with a spectrum analyser is presented, and its 
functionalization for DNA detection described. As far as we are aware this is the first time experimental results for DNA 
hybridization sensing have been shown for such a device. If the preliminary result of 5pM detection of 25mers ssDNA is 
confirmed in further experiments underway for full analytical data, it would be superior than what we understand to be 
the best published limit of detection to date of 10pM of 58mers. That with said the preliminary data is sufficient to 
demonstrate the suitability of the biosensors for their integration into the CanDo device. 
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